Abstract:Immunostimulatory cues play an important role in priming antitumor immunity and promoting the efficacy of subunit cancer vaccines. However, the clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote vaccine efficacy, we develop vaccine formulations which integrate three key elements: (1) a nano-adjuvant formulated by conjugating an agonistic anti-CD40 monoclonal antibody (αCD40) to the surface of a polyIC-loaded lipid nanoparticle, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope that derived from a melanoma antigen gp100, (3) an agonistic anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In a syngeneic mouse model of melanoma, the vaccine formulations enhanced innate immunity and activated multiple innate immune signaling pathways within draining lymph nodes, as well as promoted antigen-specific immune responses and reduced immunosuppression in the tumor microenvironment, leading to profound tumor growth inhibition and prolonged survival. Thus, our vaccine formulations represent an attractive strategy to stimulate antitumor immunity and control tumor progression. Statement of significance The clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote the antitumor immunity of subunit vaccines, we develop novel vaccine formulations that integrate multifunctional modalities including (1) a nano-adjuvant containing anti-CD40 monoclonal antibody (αCD40) and TLR3 agonist which activate innate immunity through diverse signaling pathways, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope from tumor antigen, (3) an anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In this study, our vaccine formulations stimulate superior antitumor immunity and control tumor progression. The above nano-engineered platform and immunogenic biomacromolecules can be further applied to other T-cell-inducing vaccines.

Vaccine Delivery: Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8+ T Cell Responses (adv. Sci. 1/2018)

Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8 + T Cell Responses

Vaccination-Route-Dependent Adjuvanticity of Antigen-Carrying Nanoparticles for Enhanced Vaccine Efficacy

Whole‐Cell‐Mimicking Carrier‐Free Nanovaccines Amplify Immune Responses Against Cancer and Bacterial Infection

Improving Cancer Vaccine Efficiency by Nanomedicine

Hollow Aluminum Hydroxide Modified Silica Nanoadjuvants with Amplified Immunotherapy Effects through Immunogenic Cell Death Induction and Antigen Release

Development of Multistaged Nanoparticles As Cancer Vaccines : International School of Nanomedicine

Dictating the spatial-temporal delivery of molecular adjuvant and antigen for the enhanced vaccination

Nanovaccines: Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy (adv. Mater. 7/2017)

In Situ Programming of Nanovaccines for Lymph Node-Targeted Delivery and Cancer Immunotherapy

Immunostimulatory DNA Nanogel Enables Effective Lymphatic Drainage and High Vaccine Efficacy

An antigen self-assembled and dendritic cell-targeted nanovaccine for enhanced immunity against cancer

Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity.

Two‐Pronged Intracellular Co‐Delivery of Antigen and Adjuvant for Synergistic Cancer Immunotherapy

Antigen-caged-adjuvant nanovaccines elicit potent humoral and cellular immune responses

Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Adjuvant physiochemistry and advanced nanotechnology for vaccine development

Self-adjuvanting Polymeric Nanovaccines Enhance IFN Production and Cytotoxic T Cell Response.

Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response

Nanotechnology-Assisted Immunoengineering for Cancer Vaccines